phocytes alveolitis of granulomatous lung disorders are polyclonal or oligoclonal, we analyzed DNAextracted from T cells obtained by bronchoalveolar lavage in patients with sarcoidosis and farmer's lung disease. Southern blot hybridization with T cell receptor gene probe gave no signals derived from the specific rearrangement, indicating polyclonal expansion of lung T cells (Fig. 1 Miyamoto et al (1) have conducted a dose-finding study of OKY-046 (2, 3), a specific thromboxane (Tx) synthetase inhibitor, in 240 adult patients with asthma on a similar design and revealed that the drug is most effective in a daily dosage of 400 mg given in two divided doses in the morning and before bedtime. In order to see if it is possible to assess the usefulness of the drug with high accuracy in a smaller number of subjects at a single institution, we have conducted a placebo-controlled doubleblind study in a small series of patients at our department.
PATIENTS AND METHODS
The study excluded those patients who take a large amount of a steroid continuously, regardless of severity and type of the disease. It consisted of a 4-week observation period and a 12-week treatment period. The clinical data were collected from 25 cases in the OKY-046 group and 24 cases in the placebo group, totaling 49 cases. Of these, statistical analysis was made in 42 cases, and final overall improvement rating could be done in 40 cases. No significant difference was observed between the two groups in the type of disease, atopic, infectious and mixed type, and the severity of disease. A tool used to evaluate the efficacy of the two study regimens was the patient's diary which recorded symptoms and concomitant medication. An asthma score was calculated based on these records.
Physician assessment of the clinical state of the patient was done by the same investigator who directed the whole study and followed up on all the subjects over the course of treatment.
RESULTS
The proportions of moderately to markedly improved cases and slightly to markedly improved cases in the OKY-046 group were 33.3 and 66.7%, respectively, and those in the placebo group were 10.5 and 21.1%. Thus the OKY-046 group showed a significantly higher improvement rate. This improvement rate was lower than that observed in the previous report of Miyamoto et al. (1) (Fig. 1) . This is likely due to a smaller number of subjects in the present study and the fact that this study included manypatients with an infectious type or mixed type of asthma, although the efficacy in patients with either type was similar to that with an atopic type. The asthma score remained unchanged or increased in the placebo group even after the start of the treatment, while that of the OKY-046group decreased at weeks 9-12 of treatment. No significant difference, however, was noted statistically.
The main urinary metabolite of TxA2, 2,3-dinorTxB2was measured before and after administration of the drug to study any relationship between the treatment and the improvement rating in asthma. improvement from their pretreatment condition. The OKY-046 group showed a significantly higher improvement than the placebo group. The result was similar to that shownin the previous multicenter study in a larger numberof subjects.
